USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS
The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
1 - 17 . (canceled)
18 . A pharmaceutical composition for altering microbiota comprising:
a therapeutically effective amount of a substantially purified Akkermansia , wherein the substantially purified Akkermansia comprises at least 50% of a strain of Akkermansia,
a prebiotic, and
a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is formulated for oral delivery and encapsulated by a coating, wherein the coating does not fully degrade until after it exits the stomach of a subject.
19 . The pharmaceutical composition of claim 18 , further comprising at least one of a substantially purified Bacteroidetes , a substantially purified Firmicutes and a substantially purified Proteobacteria.
20 . The pharmaceutical composition of claim 19 , wherein the substantially purified Bacteroidetes is Bacteroidales , the substantially purified Firmicutes is Clostridiales and the substantially purified Proteobacteria is Enterobacteriales.
21 . The pharmaceutical composition of claim 19 , wherein the substantially purified Bacteroidetes is Alistipes , the substantially purified Firmicutes is Clostridium and the substantially purified Proteobacteria is Escherichia.
22 . The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition alters the relative abundance of at least one of Bacteroidetes, Verrucomicrobia, Firmicutes, Tenericutes , and Proteobacteria in a gastrointestinal tract of a subject.
23 . The pharmaceutical composition of claim 18 , wherein the prebiotic is a non-digestible oligosaccharide.
24 . The pharmaceutical composition of claim 23 , wherein the non-digestible oligosaccharide is a fructooligosaccharide, a glucooligosaccharide, a xylooligosaccharide, a galactooligosaccharide, an arabinoxylan, an arabinogalactan, a galactomannan, a polydextrose, an oligofructose, inulin, and/or a derivative thereof.
25 . The pharmaceutical composition of claim 23 , wherein the non-digestible oligosaccharide is a fructooligosaccharide.
26 . The pharmaceutical composition of claim 18 , wherein the prebiotic is inulin.
27 . The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition is formulated for delivery to a small intestine, a large intestine, an ileum, a cecum, or a colon region of a subject.
28 . The pharmaceutical composition of claim 27 , wherein the pharmaceutical composition is formulated for delivery to an ileum or a colon region of a subject.
29 . The pharmaceutical composition of claim 18 , further comprising substantially purified Firmicutes.
30 . The pharmaceutical composition of claim 29 , wherein the substantially purified Firmicutes is substantially purified Clostridiales.
31 . The pharmaceutical composition of claim 30 , wherein the pharmaceutical composition comprises between about 30% and about 60% substantially purified Clostridiales.
32 . The pharmaceutical composition of claim 29 , wherein the substantially purified Firmicutes is substantially purified Clostridium.
33 . The pharmaceutical composition of claim 32 , wherein the pharmaceutical composition comprises between about 30% and about 50% substantially purified Clostridium.
34 . The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition increases a relative abundance of Clostridium in a subject.
35 . The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition increases glucose metabolism in a subject.
36 . The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition increases energy expenditure in a subject.
37 . The pharmaceutical composition of claim 18 , wherein the Akkermansia is lyophilized.
38 . The pharmaceutical composition of claim 18 , wherein if the composition comprises a mixture of bacterial strains, then at least 50% of the bacterial strains in the composition are Verrucomicrobia, Bacteroidetes, Firmicutes , or Proteobacteria.
39 . The pharmaceutical composition of claim 18 , wherein the Akkermansia is viable.
40 . The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises two or more bacterial strains, wherein the two or more bacterial strains exhibit a synergistic effect in the pharmaceutical composition.
41 . A pharmaceutical composition for altering microbiota comprising:
a therapeutically effective amount of a substantially purified Akkermansia , wherein the substantially purified Akkermansia comprises at least 50% of a strain of Akkermansia,
a prebiotic, and
a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is formulated for oral delivery and encapsulated by a coating.
42 . The pharmaceutical composition of claim 41 , further comprising at least one of a substantially purified Bacteroidetes , a substantially purified Firmicutes and a substantially purified Proteobacteria.
43 . The pharmaceutical composition of claim 41 , wherein the pharmaceutical composition alters the relative abundance of at least one of Bacteroidetes, Verrucomicrobia, Firmicutes, Tenericutes , and Proteobacteria in a gastrointestinal tract of a subject.
44 . The pharmaceutical composition of claim 41 , wherein the prebiotic is a non-digestible oligosaccharide selected from the group consisting a fructooligosaccharide, a glucooligosaccharide, a xylooligosaccharide, a galactooligosaccharide, an arabinoxylan, an arabinogalactan, a galactomannan, a polydextrose, an oligofructose, inulin, and/or a derivative thereof.
45 . The pharmaceutical composition of claim 41 , wherein the pharmaceutical composition is formulated for delivery to a small intestine, a large intestine, an ileum, a cecum, or a colon region of a subject.
46 . The pharmaceutical composition of claim 41 , wherein the pharmaceutical composition increases glucose metabolism or energy expenditure in a subject.
47 . The pharmaceutical composition of claim 41 , wherein the Akkermansia is viable or non-viable.